Recursion Announces Plans to Open New Office in London
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: GlobeNewswire
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company’s artificial intelligence research engine, access to world-class talent across Europe’s rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies. "As Recursion continues to lead and define the TechBio industry, it's critical we hire the best possible talent, much of which is located in Europe," said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. "London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicenter for the rapidly growing TechBio sector in Europe
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Where Will Recursion Pharmaceuticals Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewswire
- Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/27/24 - Beat
RXRX
Sec Filings
- 4/25/24 - Form 3
- 4/25/24 - Form 144
- 4/23/24 - Form ARS
- RXRX's page on the SEC website